Over 38 million adults in the United States have diabetes, according to the Centers for Disease Control and Prevention. Furthermore, the prevalence of diabetes has been steadily rising, increasing…
Anti-obesity drugs are showing promise for a growing list of conditions. In The Wall Street Journal, AACE President Scott D. Isaacs, MD, FACP, FACE, discusses the expanding role of GLP-1…
As Ozempic and other GLP-1 weight-loss injections continue to gain popularity, users are reporting a curious side effect that has nothing to do with numbers on the scale: a dramatic shift in their…
In this episode of the Frontline Gastroenterology podcast, AACE President Scott D. Isaacs, MD, FACP, FACE, discusses the use of anti-diabetic medications such as pioglitazone or GLP-1…
Whether you're a health care professional looking to introduce CGM into your practice or a patient exploring your options, this step-by-step guide will help you get started with confidence. Learn how…
In a recent article by The Guardian, AACE President Scott D. Isaacs, MD, FACP, FACE, joins experts in responding to new research indicating that more than 15 million people in the US, UK,…
As part of treating the overall well-being of your patients, it may be beneficial to recommend nutritional counseling. More insurance carriers are providing this service as a benefit. AACE President…
New research found a link between GLP-1 use in people with diabetes and an elevated chance of wet AMD, which can cause blindness. AACE President Scott D. Isaacs, MD, FACP, FACE, explains that while…
Shortages of name-brand obesity drugs sparked a surge in online sales of compounded alternatives. In a recent NPR report, AACE President Scott D. Isaacs, MD, FACP, FACE, expressed concern about these…
Watch this MedPage Today interview with AACE President Scott D. Isaacs, MD, FACP, FACE, as he recaps key takeaways from the recent AACE Annual Meeting. He discusses the meeting’s theme of endocrine…